Search results
EU approves BeiGene's tislelizumab for lung cancer By Investing.com
Investing.com· 7 days agoThe European Commission (EC) has granted approval to tislelizumab for the treatment of non-small...
TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the...
Digital Journal· 5 days agoTAMPA, FL and SAN DIEGO, CA / ACCESSWIRE / April 25, 2024 / TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome ...
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
Zacks· 21 hours agoInvestors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday? - HOOKIPA Pharma (NASDAQ:HOOK)
Benzinga· 5 days agoWednesday, HOOKIPA Pharma Inc HOOK received clearance from the FDA for its Investigational New Drug...
‘They didn't choose to be victims’: Supporters brave the cold to spread awareness
Wyoming Tribune-Eagle· 15 hours agoParticipants were not worried about being at the mercy of wind and rain; they still saw it as a...
Gilead gives up on $4.9B antibody as solid tumor plan unravels
FierceBiotech· 4 days agoA $4.9 billion hole has appeared in Gilead’s pipeline. After years of setbacks, the big biotech dealt a final blow to its anti-CD47 monoclonal antibody magrolimab Thursday by removing the remaining ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 6 days agoNew York, USA, April 24, 2024 (GLOBE NEWSWIRE) -- HDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the growth of the HDAC inhibitors market is expected
HC Wainwright Reaffirms “Buy” Rating for Purple Biotech (NASDAQ:PPBT)
ETF DAILY NEWS· 21 hours agoHC Wainwright reaffirmed their buy rating on shares of Purple Biotech (NASDAQ:PPBT – Free Report) in a report issued on Friday, Benzinga reports. HC Wainwright currently has a $10.00 price target ...
2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor
FOX 4 Kansas City· 5 days agoMabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain,...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in...
Morningstar· 2 days agoPomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT) and certain officers. The class action ...